Multiple Myeloma Hub
How to select maintenance therapies post-ASCT for patients with high-risk MM?
Sep 18, 2023
Experts Shaji Kumar and Naresh Bumma discuss selecting maintenance therapies post-ASCT for high-risk MM. They debate lenalidomide monotherapy vs. combination therapy with a proteosome inhibitor, the challenges of defining high-risk populations, and the need for prospective trials. Kumar and Bumma share their management strategies and highlight the future of managing high-risk MM post-ASCT.
20:31
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Defining high-risk MM challenges include varied cytogenetic definitions, like 17p deletions and translocations, prompting a need for consensus statements.
- The benefits of combination maintenance therapies, including bortezomib and lenalidomide, are crucial for achieving deeper responses in high-risk MM patients post-ASCT.
Deep dives
Challenges in Defining High-Risk Patients
Defining high-risk multiple myeloma patients presents challenges due to varying definitions of high-risk cytogenetics, including factors like 17p deletions, translocation 4;14, translocation 14;16, and gain 1q. Ambiguities exist in classifying 1q gain and amplification. Discussions are ongoing to establish consensus statements to bring clarity and consistency to clinical trials.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
